Forty Seven Inc (FTSV) Insider Chris H. Takimoto Sells 8,000 Shares

Forty Seven Inc (NASDAQ:FTSV) insider Chris H. Takimoto sold 8,000 shares of the company’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $17.99, for a total value of $143,920.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Forty Seven stock opened at $18.65 on Friday. Forty Seven Inc has a 52 week low of $12.02 and a 52 week high of $23.83. The firm has a market capitalization of $584.85 million and a PE ratio of -4.97.

Forty Seven (NASDAQ:FTSV) last announced its quarterly earnings results on Thursday, March 28th. The company reported ($0.56) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.66) by $0.10. Sell-side analysts expect that Forty Seven Inc will post -2.61 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. bought a new position in shares of Forty Seven during the first quarter valued at approximately $32,000. BlackRock Inc. grew its holdings in shares of Forty Seven by 34.7% during the first quarter. BlackRock Inc. now owns 1,139,596 shares of the company’s stock valued at $18,416,000 after purchasing an additional 293,642 shares during the last quarter. California State Teachers Retirement System grew its holdings in shares of Forty Seven by 65.4% during the first quarter. California State Teachers Retirement System now owns 21,692 shares of the company’s stock valued at $351,000 after purchasing an additional 8,576 shares during the last quarter. TD Asset Management Inc. grew its holdings in Forty Seven by 8.1% in the 1st quarter. TD Asset Management Inc. now owns 14,637 shares of the company’s stock worth $237,000 after buying an additional 1,100 shares in the last quarter. Finally, Exane Asset Management grew its holdings in Forty Seven by 148.1% in the 1st quarter. Exane Asset Management now owns 67,000 shares of the company’s stock worth $1,083,000 after buying an additional 40,000 shares in the last quarter. 43.17% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have issued reports on FTSV shares. Oppenheimer set a $35.00 target price on Forty Seven and gave the company a “buy” rating in a report on Friday, January 11th. HC Wainwright restated a “buy” rating and issued a $21.00 target price on shares of Forty Seven in a report on Monday, January 14th. Zacks Investment Research cut Forty Seven from a “hold” rating to a “sell” rating in a report on Tuesday, January 15th. FIG Partners assumed coverage on Forty Seven in a report on Friday, February 1st. They issued a “buy” rating and a $30.00 target price for the company. Finally, Guggenheim assumed coverage on Forty Seven in a research note on Friday, April 12th. They issued a “buy” rating on the stock. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $26.75.

COPYRIGHT VIOLATION NOTICE: “Forty Seven Inc (FTSV) Insider Chris H. Takimoto Sells 8,000 Shares” was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/05/10/forty-seven-inc-ftsv-insider-chris-h-takimoto-sells-8000-shares.html.

About Forty Seven

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody.

Read More: Why do company’s buyback their stock?

Insider Buying and Selling by Quarter for Forty Seven (NASDAQ:FTSV)

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.